Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report:June 3, 2004
(Date of earliest event reported)
GTx, Inc.
Delaware | 005-79588 | 62-1715807 | ||
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) |
3 N. Dunlap Street
3rd Floor, Van Vleet Building
Memphis, Tennessee 38163
(901) 523-9700
including area code, of registrant’s principal executive offices)
ITEM 7 Financial Statements and Exhibits | ||||||||
ITEM 9 Regulation FD Disclosure | ||||||||
SIGNATURE | ||||||||
Ex-99.1 Press Release |
Table of Contents
ITEM 7 | Financial Statements and Exhibits |
(c) | Exhibits |
Exhibit | ||
Number | Description | |
99.1 | Press Release issued by GTx, Inc. dated June 2, 2004 |
ITEM 9 | Regulation FD Disclosure |
On June 2, 2004, GTx announced information regarding the positive results of its Phase IIb clinical trials of Acapodene™ for the prevention of prostate cancer in high risk men. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Table of Contents
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GTx, Inc. | ||||
Date: June 3, 2004 | By: | /s/ Henry P. Doggrell | ||
Name: | Henry P. Doggrell | |||
Title: | General Counsel/Secretary | |||